Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· April 14, 2026

Stocks Rally on a Push for Diplomacy to End US-Iran War

View original at nasdaq.com
Stocks Rally on a Push for Diplomacy to End US-Iran War The S&P 500 Index ($SPX) (SPY) on Tuesday closed up +1.18%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.66%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.81%…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Would target all ports in and close to Persian Gulf if its own shipping hubs are threatened

    60% confidence
  • Talks with Iran could resume over the next two days in Pakistan

    60% confidence
  • Eurozone economy is between the baseline and adverse projections in ECB's base case, reflecting the war in Iran

    60% confidence
  • Q1 S&P 500 earnings projected to climb +12% year-over-year

    60% confidence
  • Denied report that it was seeking to acquire Dell Technologies or HP Inc

    60% confidence
  • Floated a possible combination with American Airlines

    60% confidence
  • Stripping out technology sector, Q1 earnings projected to increase around 3%, the weakest in two years

    60% confidence
  • Will not vote in favor of Kevin Warsh until Trump administration drops threat to prosecute Fed Chair Powell for cost overruns on Fed building

    60% confidence
  • Optimistic that Trump administration will soon drop investigation into Fed Chair Powell

    60% confidence
  • Faster inflation due to Iran war doesn't make an interest rate hike self-evident

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com